Last reviewed 2026-04-20 · How we verify

Chlortermine (CLORTERMINE)

Phase 2 active Small molecule

Chlortermine (generic name: CLORTERMINE) is a clortermine drug. It is currently in Phase 2 development for Anorexia nervosa.

Chlortermine works by increasing appetite and food intake in individuals with anorexia nervosa.

Chlortermine, also known as CLORTERMINE, is a small molecule drug in the clortermine class. It is used to treat anorexia nervosa, a serious eating disorder. The commercial status of Chlortermine is currently unknown, and it is not clear if it is patented or available as a generic medication. Further information on its pharmacokinetics and safety profile is also lacking. As a result, its use should be approached with caution.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLORTERMINE
Drug class	clortermine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In simple terms, Chlortermine helps people with anorexia nervosa feel hungrier and want to eat more. This is achieved by affecting the brain's appetite centers, which can help restore a healthy weight and reduce the risk of related health problems. By increasing food intake, Chlortermine can help individuals with anorexia nervosa recover from their condition.

Approved indications

Anorexia nervosa

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chlortermine CI brief — competitive landscape report
Chlortermine updates RSS · CI watch RSS

Frequently asked questions about Chlortermine

What is Chlortermine?

Chlortermine (CLORTERMINE) is a clortermine drug, indicated for Anorexia nervosa.

How does Chlortermine work?

Chlortermine works by increasing appetite and food intake in individuals with anorexia nervosa.

What is Chlortermine used for?

Chlortermine is indicated for Anorexia nervosa.

What is the generic name of Chlortermine?

CLORTERMINE is the generic (nonproprietary) name of Chlortermine.

What drug class is Chlortermine in?

Chlortermine belongs to the clortermine class. See all clortermine drugs at /class/clortermine.

What development phase is Chlortermine in?

Chlortermine is in Phase 2.

Drug class: All clortermine drugs
Therapeutic area: All drugs in Other
Indication: Drugs for Anorexia nervosa

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing